H Yu1, D MacIsaac1,2, J J Wong3, Z M Sellers1, A A Wren1, R Bensen1, C Kin2, K T Park1. 1. Stanford Children's Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. 2. Division of Colorectal Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA. 3. Center for Health Policy, Department of Medicine, Palo Alto Veterans Affairs, Stanford University School of Medicine, Stanford, CA, USA.
Abstract
BACKGROUND: Real-world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown. AIM: To determine the outpatient IBD drug utilization trends, relative market share, and costs in the USA during a 9-year period. METHODS: The Truven MarketScan® Database was analysed for patients with Crohn's disease (CD) and ulcerative colitis (UC) during 2007-2015. National drug codes were used to identify prescription drugs; Healthcare Common Procedure Coding System J-codes were used to capture biologic out-patient infusions. Proportion of drug usage, relative market share and per-member per-year (PMPY) costs were analysed for biologics, immunomodulators, 5-ASAs and corticosteroids. RESULTS: In 415 405 patients (188 842 CD; 195 183 UC; 31 380 indeterminate colitis; 54.67% female), utilization trends show a consistent rise in the market share of biologics during the 9-year study period. The proportion of patients using biologics increased from 21.8% to 43.8% for CD and 5.1%-16.2% for UC. This contrasts a small decrease in immunomodulator and 5-ASA use for CD and relative constancy of other classes including corticosteroids-only use as primary IBD medication from 2007 to 2015. The average biologic-taking patient accounted for $25 275 PMPY in 2007 and $36 051 PMPY in 2015. The average paediatric biologic-taking patient accounted for $23 616 PMPY in 2007 and $41 109 PMPY in 2015. In all patients, the share of costs for biologics increased from 72.9% in 2007 to 85.7% in 2015 (81.7% in 2007 to 94.9% in 2015 in paediatrics). CONCLUSION: The vast majority of costs allocated to out-patient IBD medications in the USA is attributed to increasing use of biologic therapies despite the relative minority of biologic-taking patients.
BACKGROUND: Real-world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown. AIM: To determine the outpatient IBD drug utilization trends, relative market share, and costs in the USA during a 9-year period. METHODS: The Truven MarketScan® Database was analysed for patients with Crohn's disease (CD) and ulcerative colitis (UC) during 2007-2015. National drug codes were used to identify prescription drugs; Healthcare Common Procedure Coding System J-codes were used to capture biologic out-patient infusions. Proportion of drug usage, relative market share and per-member per-year (PMPY) costs were analysed for biologics, immunomodulators, 5-ASAs and corticosteroids. RESULTS: In 415 405 patients (188 842 CD; 195 183 UC; 31 380 indeterminate colitis; 54.67% female), utilization trends show a consistent rise in the market share of biologics during the 9-year study period. The proportion of patients using biologics increased from 21.8% to 43.8% for CD and 5.1%-16.2% for UC. This contrasts a small decrease in immunomodulator and 5-ASA use for CD and relative constancy of other classes including corticosteroids-only use as primary IBD medication from 2007 to 2015. The average biologic-taking patient accounted for $25 275 PMPY in 2007 and $36 051 PMPY in 2015. The average paediatric biologic-taking patient accounted for $23 616 PMPY in 2007 and $41 109 PMPY in 2015. In all patients, the share of costs for biologics increased from 72.9% in 2007 to 85.7% in 2015 (81.7% in 2007 to 94.9% in 2015 in paediatrics). CONCLUSION: The vast majority of costs allocated to out-patient IBD medications in the USA is attributed to increasing use of biologic therapies despite the relative minority of biologic-taking patients.
Authors: Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn Journal: Gastroenterology Date: 2011-06-30 Impact factor: 22.682
Authors: J Kirchgesner; M Lemaitre; A Rudnichi; A Racine; M Zureik; F Carbonnel; R Dray-Spira Journal: Aliment Pharmacol Ther Date: 2016-10-26 Impact factor: 8.171
Authors: Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert Van Assche; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts Journal: Inflamm Bowel Dis Date: 2009-09 Impact factor: 5.325
Authors: Michael D Kappelman; Sheryl L Rifas-Shiman; Ken Kleinman; Dan Ollendorf; Athos Bousvaros; Richard J Grand; Jonathan A Finkelstein Journal: Clin Gastroenterol Hepatol Date: 2007-09-29 Impact factor: 11.382
Authors: Christopher Ma; Matthew K Smith; Leonardo Guizzetti; Remo Panaccione; Gilaad G Kaplan; Kerri L Novak; Cathy Lu; Reena Khanna; Brian G Feagan; Siddharth Singh; Vipul Jairath; Ashwin N Ananthakrishnan Journal: Clin Gastroenterol Hepatol Date: 2020-01-25 Impact factor: 11.382
Authors: Edward L Barnes; Yue Jiang; Michael D Kappelman; Millie D Long; Robert S Sandler; Alan C Kinlaw; Hans H Herfarth Journal: Inflamm Bowel Dis Date: 2020-07-17 Impact factor: 5.325
Authors: Kevin T Kline; Haifeng Lian; Xiaoying S Zhong; Xiuju Luo; John H Winston; Yingzi Cong; Tor C Savidge; Roderick H Dashwood; Don W Powell; Qingjie Li Journal: J Immunol Date: 2019-12-30 Impact factor: 5.422
Authors: S Ballou; W Hirsch; P Singh; V Rangan; J Nee; J Iturrino; T Sommers; J Zubiago; N Sengupta; A Bollom; M Jones; A C Moss; S N Flier; A S Cheifetz; A Lembo Journal: Aliment Pharmacol Ther Date: 2018-02-07 Impact factor: 8.171
Authors: Sara Gaines; Sanjiv Hyoju; Ashley J Williamson; Jasper B van Praagh; Olga Zaborina; David T Rubin; John C Alverdy; Benjamin D Shogan; Neil Hyman Journal: J Gastrointest Surg Date: 2020-01-02 Impact factor: 3.452